Clinical Trial

A Study to Assess the Pharmacokinetics of GEn-1124 After Single Oral Dosing in Healthy Subjects

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to determine the pharmacokinetics (how the body interacts with administered substances for the entire duration of exposure) of Gen-1124 in an oral formulation (taken by mouth) in healthy volunteers. It will also learn about the safety of Gen-1124. The main questions it aims to answer are: \- How does Gen-1124 interact with a human body? Researchers will look at how Gen-1124 interacts with the body and what side effects it may cause. Participants will: * Take Gen-1124 for a single dose * Remain in clinic for 2 days for checkups and tests * Recieve a phone call for a checkup 3 and 7 days after the single dose
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-17; most recent amendment 2026-05-14.
Status change: Recruiting → Completed 2026-05-14
Status change: Not Yet Recruiting → Recruiting 2025-12-10
Trial Details
NCT Number NCT07185113
Lead Sponsor GEn1E Lifesciences
Collaborators: InClin, Inc.
Conditions Healthy Adult Male
Enrollment 6 participants
Start Date 2025-10-29
Primary Completion 2025-11-04 (estimated)
Study Completion 2025-11-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-15